Details

Autor(en) / Beteiligte

• Chen, Jiajun
• Cui, Yunxi
• Wu, Peixuan
• Dassanayake, Rohan
• Yu, Peng
• Fu, Kun
• Sun, Zhicheng
• Liu, Yuanyuan
• Zhou, Yang

Titel

Nitroxyl donating and visualization with a coumarin-based fluorescence probe

Ist Teil von

• Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2024-08, Vol.316, Article 124317

Ort / Verlag

Elsevier B.V

Erscheinungsjahr

2024

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• [Display omitted] •The first coumarin-based HNO donor (CD1) was developed.•HNO-releasing has a t1/2 ∼90 min under physiological conditions.•The fluorescence intensity increased by about 4.9-fold.•HNO release can be visualized by cellar images. Nitroxyl (HNO), the single-electron reduction product of nitric oxide (NO), has attracted great interest in the treatment of congestive heart failure in clinical trials. In this paper, we describe the first coumarin-based compound N-hydroxy-2-oxo-2H-chromene-6-sulfonamide (CD1) as a dualfunctional HNO donor, which can release both an HNO signaling molecule and a fluorescent reporter. Under physiological conditions (pH 7.4 and 37 °C), the CD1 HNO donor can readily decompose with a half-life of ∼90 min. The corresponding stoichiometry HNO from the CD1 donor was confirmed using both Vitamin B12 and phosphine compound traps. In addition to HNO releasing, specifically, the degradation product 2-oxo-2H-chromene-6-sulfinate (CS1) was generated as a fluorescent marker during the decomposition. Therefore, the HNO amount released in situ can be accurately monitored through fluorescence generation. As compared to the CD1 donor, the fluorescence intensity increased by about 4.9-fold. The concentration limit of detection of HNO releasing was determined to be ∼0.13 μM according to the fluorescence generation of CS1 at physiological conditions. Moreover, the bioimaging of the CD1 donor was demonstrated in the cell culture of HeLa cells, where the intracellular fluorescence signals were observed, inferring the site of HNO release. Finally, we anticipate that this novel coumarin-based CD1 donor opens a new platform for exploring the biology of HNO.